Aurora Cannabis Acquisition of Reliva Closes
Aurora Cannabis' (NYSE: ACB) latest asset buy is in the books. The company announced on Thursday that its purchase of Reliva, a maker of hemp-derived cannabidiol (CBD) products, has closed.
The news comes just over a week after Aurora divulged that it and Reliva had agreed to the acquisition. The basic terms of the deal are that Aurora is to pay $40 million in common stock for Reliva, with potentially as much as $45 million more if the latter hits certain financial incentives across the following two years. Those additional monies, if earned, will be paid either in cash, stock, or a combination of the two.
A field of hemp, which provides the CBD for Reliva's products. Image source: Getty Images.
Source Fool.com
